Part 2 - SECRET VACCINE CONTRACTS: IOJ Found The Mutual Vaccine Confidentiality Arrangements between FDA, HHS and the World Health Organization. IOJ Is Demanding Their Disclosure.
Yes, IOJ is requesting the documents by FOIA, but we are also filing an action in Costa Rica's international court & request our judge to order the Mutual Confidentiality Agreements IMMEDIATE release.
First, in part 1 we outlined how freedom of information requests uncovered that CDC official, after official, after official were getting notified that doctors around the country are seeing problems, especially young people having swollen hearts as a result of getting the covid vaccine. Some documents came out last week or earlier this week where our folks in the U.S Public Health establishment, the central advisory body for covid, about advising the government whether to approve it, or how to handle it, was communicating in December 2020 with their counterparts in the United Kingdom about anaphylactoid reactions.
In the emails they [UK & US regulatory] talk about sharing information, but both of them were concerned about this Mutual confidentiality agreement in the discussion.
See the FDA -UK confidentiality agreement they were freaking out about, from 2017, here:
But that’s not all folks,
Interest of Justice has found some more of the Mutual confidentiality agreements that U.S. and U.K. public health officials were discussing in regards to vaccine injury potentials. We actually found it a few weeks ago, and now with the Judicial Watch emails coming out with U.S. and U.K. regulatory agencies discussing vaccine injuries in the context of Mutual Confidentiality agreements, it is clearly time to back up Judicial Watch and raise HELL.
Yes, IOJ is filing FOIA Requests To Get The Following Mutual Confidentiality Agreements Between USA Health Agencies And The WHO/UN!
Next, we are filing a claim in Costa Rica’s international court for the “secret” information….
The FOIA’s will never work and we all know it.
* More on our filings of these critical legal actions in an upcoming post.
Back to the story:
Apparently FDA and WHO like to keep secrets about vaccines, which, in our opinion, likely includes their knowledge of serious possible and actual injuries.
Let’s Get Into It:
Apparently, For Each Mutual Confidentiality Agreement There Is “The Arrangement”…
And There Are “The Participants”…
Don’t Forget The “Purpose”…
Whereas HHS/FDA and WHO/IVB/QSS are willing to disclose Information to each other for the sole purpose of undertaking discussions aimed at coordinating and facilitating HHS/FDA's regulatory activities and WHO/IVB/QSS pre-qualification activities (hereinafter referred to as "the Purpose").
and in another mutual confidentiality agreement the purpose is:
Whereas the United States Food and Drug Administration (FDA) and the World Health Organization, through its Department of Essential Medicines and Health Products (WHO/EMP) (jointly, “the Participants”) are willing to disclose information to each other for the sole purpose of undertaking discussions aimed at coordinating and facilitating FDA’s regulatory activities on the one hand, and the activities of WHO/EMP’s International Nonproprietary Name (INN) Programme relating to the identification of pharmaceutical substances and active pharmaceutical ingredients on the other hand (hereinafter referred to as “the Purpose”).
The Plot Thickens As Far As Mutual Confidentiality Agreements Regarding Vaccines…
Check out some of the more interesting FDA confidentiality agreements regarding vaccines with the World Health Organization that we found!
FDA - WHO/IVB/QSS, Mutual Confidentiality Commitment
MUTUAL CONFIDENTIALITY ARRANGEMENT AND COMMITMENT NOT TO PUBLICLY DISCLOSE NON-PUBLIC INFORMATION SHARED BY AND BETWEEN THE U.S. FOOD AND DRUG ADMINISTRATION WITHIN THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES AND THE QUALITY SAFETY AND STANDARDS UNIT OF THE DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS OF THE WORLD HEALTH ORGANIZATION
Whereas as part and in the course of the discussions between the United States Food and Drug Administration within the Department of Health and Human Services (HHS/FDA) and the Quality Safety and Standards Unit of the Department of Immunization, Vaccines And Biologicals of the World Health Organization (WHO/IVB/QSS), aimed at coordinating and facilitating the HHS/FDA's regulatory activities and WHO/IVB/QSS activities to assess the acceptability in principle of vaccines for procurement by United Nations (UN) Agencies (hereinafter also referred to as WHO/IVB/QSS "pre-qualification activities"), each party may (as "the Disclosing Party") disclose to the other party (as "the Receiving Party") certain information relating to its aforesaid activities that it considers non-public, confidential or proprietary to it or parties collaborating with it.
Whereas the aforesaid information may include confidential product and/or commercial information; trade secret information; personal privacy information; law enforcement information, and/or internal, pre-decisional information.
Whereas the Disclosing Party will advise the Receiving Party of the non-public, proprietary or confidential nature of the information it intends to disclose, at the time of disclosure. In addition, the Disclosing Party will mark the information in question as confidential, or in the case of oral disclosure, will confirm the non-public, proprietary or confidential nature of the information to the Receiving Party in writing within 15 (fifteen) calendar days after oral disclosure. Any information of the type described in the previous paragraph and designated by HHS/FDA or WHO/IVB/QSS, as the case may be, as non-public, proprietary or confidential as aforesaid is hereinafter referred to as "Information".
Whereas HHS/FDA and WHO/IVB/QSS are willing to disclose Information to each other for the sole purpose of undertaking discussions aimed at coordinating and facilitating HHS/FDA's regulatory activities and WHO/IVB/QSS pre-qualification activities (hereinafter referred to as "the Purpose").
Whereas HHS/FDA and WHO/IVB/QSS each affirm that they have the authority to protect Information from public disclosure.
Therefore, HHS/FDA and WHO/IVB/QSS each agree that in accepting Information as Receiving Party from the other as Disclosing Party, they shall abide by the following:
The Information disclosed by one Party ("the Disclosing Party") shall be treated by the Party receiving such Information ("the Receiving Party") as strictly confidential. The Receiving Party shall use such Information only for the Purpose and shall make no other use thereof unless and until a further agreement is executed with the Disclosing Party and/or, where appropriate, the owner of the Information in question permits such other use thereof. In connection with the foregoing, the Receiving Party shall restrict access to Information received from the Disclosing Party hereunder strictly to those persons within its organization (i.e., HHS/FDA or WHO/IVB/QSS, as the case may be) who have a need to know for the Purpose and are bound by similar obligations of confidentiality and restrictions on use as contained in this Arrangement. For the avoidance of doubt and for purposes of this Arrangement "persons within its organization" shall, for WHO/IVB/QSS, include WHO/IVB/QSS experts and temporary advisers (provided always, of course, that such experts and temporary advisers have a need to know for the Purpose and are bound by similar obligations of confidentiality and restrictions on use as contained in this Arrangement).
The worlds foremost vaccine “advisor”, Mr. Bill Gates!
Question: Does Bill Gates have a need to know for the Purpose and is he bound by similar obligations of confidentiality and restrictions on use as contained in this Arrangement???
“For the avoidance of doubt and for purposes of this Arrangement "persons within its organization" shall, for WHO/IVB/QSS, include WHO/IVB/QSS experts and temporary advisers”…. Is Bill Gates included in this agreement? People have a right to know.
The Receiving Party will not publicly disclose Information from the Disclosing Party without the written authorization of the owner of such Information, the written authorization from the individual who is the subject of the personal privacy Information, or a written statement from the Disclosing Party that the Information is no longer subject to the obligations contained herein.
Nothing in this Arrangement shall prevent the Disclosing Party from disclosing its own Information to any third party.
Nothing in this Arrangement shall be construed as a grant to the Receiving Party of any rights to the Information.
The Receiving Party undertakes to maintain the Information received from the Disclosing Party in confidence. In this regard, the Receiving Party shall take all reasonable measures to ensure that the Information shall not be used for any purpose other than the Purpose, and shall only be disclosed to persons within its organization who have a need to know for the Purpose and are bound by similar obligations of confidentiality and restrictions on use as contained in this Arrangement.
The obligations of confidentiality and restrictions on use referred to above shall not apply to any part of the Information which the Receiving Party is clearly able to, and does, demonstrate to the Disclosing Party:
was lawfully in its possession and known to it (without any obligation of confidentiality) prior to disclosure by the Disclosing Party (as evidenced by written records or other competent proof); or
was in the public domain or the subject of public knowledge at the time of disclosure by the Disclosing Party; or
becomes part of the public domain or the subject of public knowledge through no fault of the Receiving Party; or
becomes available to the Receiving Party from a third party not in breach of a legal obligation of confidentiality; or
was subsequently and independently developed by or on behalf of the Receiving Party without access to the Information of the Disclosing Party.
In addition, the Receiving Party shall be permitted to disclose Information received hereunder as may be strictly required by order of competent legislative or judicial authorities to which is it directly subject, provided that the Receiving Party shall:
immediately notify the Disclosing Party in writing of any effort made to obtain Information of the Disclosing Party by such order, and provide adequate opportunity to the Disclosing Party to object to, or restrict, such disclosure or request confidential treatment thereof; and
take all reasonable measures in an effort to ensure that the Information in question will be disclosed to such competent legislative or judicial authorities in a manner that protects such Information from public disclosure.
Upon completion of the Purpose, each Party shall, upon written request from the other Party, promptly return to the other Party, or destroy, all of the Information received from the other Party, except that each Party may retain one copy of the Information in its confidential files for archival purposes only.
Any notice to be given under this Arrangement shall be deemed to be sufficiently given for all purposes if successfully transmitted by facsimile and confirmed by mail, or if sent by registered mail or recorded delivery post (postage prepaid) addressed to the Party to be notified at the following address:
If to WHO/IVB/QSS:
Department of Immunization, Vaccines and Biologicals
Attn: Coordinator, Quality Safety and Standards:
20, avenue Appia
1211 Geneva 27 Switzerland
Te1.nr: + 41 22 791 40 50
Fax. nr: + 41 22 791 43 84
If to HHS/FDA:
Associate Commissioner for International Programs
Office of International Programs
United States Food and Drug Administration
5600 Fishers Lane (HFG-1)
Rockville, MD 20857
United States of America
Tel. +1 301-827-4480
Fax. +1 301-827-1451
This Arrangement constitutes the entire understanding of the Parties hereto with respect to the subject matter hereof and shall not be modified except by mutual agreement in writing.
The Receiving Party will promptly inform the Disclosing Party of any circumstances or changes that would affect its ability to honour the commitments in this Arrangement.
Nothing in or relating to this Arrangement shall imply an obligation on the part of WHO to submit to any national legislation or jurisdiction, or be deemed a waiver of any of the privileges and immunities of WHO under any national or international law, convention or agreement.
In the unlikely event that any difference shall arise in the interpretation or application of this Arrangement, the matter shall be submitted to the Director of the Office of Global Health Affairs within the U.S. Department of Health and Human Services and to the Director, Office of the General- Director of the World Health Organization, who will settle the question personally and jointly or through their duly authorized representatives.
Agreed and accepted on behalf of the HHS/FDA:
Signature: ----\s\----
Name: Murray M. Lumpkin, M.D., M.Sc.
Title: Deputy Commissioner
International and Special Programs
Date: Jul 08 2008
Agreed and accepted on behalf of WHO/FCH/IVB:
Signature: ----\s\---- Name: Dr. Jean-Marie Okwo-Bele
Title: Director, IVB
Date:
Download PDF here
U.S. Food and Drug Administration
Mutual Confidentiality Arrangement Between FDA And The World Health Organization
MUTUAL CONFIDENTIALITY ARRANGEMENT AND COMMITMENT NOT TO PUBLICLY DISCLOSE NON-PUBLIC INFORMATION SHARED
BY AND BETWEEN THE UNITED STATES FOOD AND DRUG ADMINISTRATION AND THE WORLD HEALTH ORGANIZATION
(“the Arrangement”)
Whereas the United States Food and Drug Administration (FDA) and the World Health Organization, through its Department of Essential Medicines and Health Products (WHO/EMP) (jointly, “the Participants”) are willing to disclose information to each other for the sole purpose of undertaking discussions aimed at coordinating and facilitating FDA’s regulatory activities on the one hand, and the activities of WHO/EMP’s International Nonproprietary Name (INN) Programme relating to the identification of pharmaceutical substances and active pharmaceutical ingredients on the other hand (hereinafter referred to as “the Purpose”).
Whereas to this end, each Participant may (as “the Disclosing Participant”) disclose to the other Participant (as “the Receiving Participant”) certain information relating to its aforesaid activities that it considers non-public, confidential or proprietary to it or parties collaborating with it.
Whereas the aforesaid information may include information protected from public disclosure, such as confidential product and/or commercial information; trade secret information; personal privacy information; law enforcement information, and/or internal, pre-decisional information.
Any information of the type described in the previous paragraph and designated by FDA or WHO/EMP, as the case may be, as non-public, proprietary or confidential as aforesaid is hereinafter referred to as “Information.”
Whereas FDA and WHO/EMP are willing to disclose Information to each other exclusively for the Purpose, subject always to the terms of this Arrangement. Whereas FDA and WHO/EMP each affirm that they have the authority to protect Information from public disclosure.
Therefore, FDA and WHO/EMP each agree that any disclosure of Information by one Participant to the other will be subject to the following terms and conditions:
Any Information which is supplied in written or other tangible form shall be clearly identified as subject to this Arrangement. Any Information which is disclosed in oral form shall be confirmed in written summary form within fifteen (15) days from the date of oral disclosure by the Disclosing Participant.
The Information disclosed by the Disclosing Participant shall be treated by the Receiving Participant as strictly confidential. The Receiving Participant shall use such Information only for the Purpose and shall make no other use thereof unless and until written permission is granted by the Disclosing Participant and, where appropriate, the owner of the Information in question permits such other use(s) thereof. In connection with the foregoing, the Receiving Participant shall restrict access to Information received from the Disclosing Participant hereunder strictly to those persons within its organization (i.e., FDA or WHO/EMP, as the case may be) who have a need to know for the Purpose and are bound by similar obligations of confidentiality and restrictions on use as contained in this Arrangement.
For the avoidance of doubt and for purposes of this Arrangement, "persons within its organization" shall include: - - For FDA: FDA officials and employees, including FDA Commissioned State Officials and Special Government Employees, and FDA contractors;
and - For WHO: WHO employees, experts, temporary advisors, consultants and contractors.
Are these the secretive FDA - WHO advisors/consultants/contractors?
The Receiving Participant will not publicly disclose Information from the Disclosing Participant without the prior written consent of the Disclosing Participant, and (where the Disclosing Participant is not the owner of the Information) the written authorization of the owner of such Information, or the written authorization from the individual who is the subject of the personal privacy Information, or a written statement from the Disclosing Participant that the Information is no longer subject to the obligations contained herein.
Nothing in this Arrangement shall prevent the Disclosing Participant from disclosing its own Information to any third party.
Nothing in this Arrangement shall be construed as a grant to the Receiving Participant of any rights to the Information.
The Receiving Participant undertakes to maintain the Information received from the Disclosing Participant in confidence. In this regard, the Receiving Participant shall take all reasonable measures to ensure that the Information shall not be used for any purpose other than the Purpose, and shall only be disclosed to persons within its organization who have a need to know for the Purpose (as defined above) and are bound by similar obligations of confidentiality and restrictions on use as contained in this Arrangement.
The obligations of confidentiality and restrictions on use referred to above shall not apply to any part of the Information which the Receiving Participant is clearly able to, and does, demonstrate to the Disclosing Participant:
was lawfully in its possession and known to it (without any obligation of confidentiality) prior to disclosure by the Disclosing Participant (as evidenced by written records or other competent proof); or
was in the public domain or the subject of public knowledge at the time of disclosure by the Disclosing Participant; or
becomes part of the public domain or the subject of public knowledge through no fault of the Receiving Participant; or
becomes available to the Receiving Participant from a third party not in breach of a legal obligation of confidentiality; or
was subsequently and independently developed by or on behalf of the Receiving Participant without access to the Information of the Disclosing Participant.
In addition, the Receiving Participant shall be permitted to disclose Information received hereunder as may be strictly required by order of competent legislative or judicial authorities to which is it directly subject, provided that the Receiving Participant shall:
immediately notify the Disclosing Participant in writing of any effort made to obtain Information of the Disclosing Participant by such order, and provide adequate opportunity to the Disclosing Participant to object to, or restrict, such disclosure or request confidential treatment thereof; and
take all reasonable measures in an effort to ensure that the Information in question will be disclosed to such competent legislative or judicial authorities in a manner that protects such Information from public disclosure (provided always, however, that nothing contained in this paragraph h shall be construed as a waiver of the privileges and immunities enjoyed by WHO and/or to submit WHO to any national court jurisdiction).
Upon completion of the Purpose and in the absence of any further written agreement between the Participants, each Participant shall cease all use, shall make no further use of the Information disclosed to it hereunder, and shall, upon written request from the other Participant, promptly return to the other Participant, or destroy, all of the Information received from the other Participant, except that each Participant may retain one copy of the Information in its confidential files to determine any continuing obligations hereunder.
Any notice to be given under this Arrangement shall be deemed to be sufficiently given for all purposes if successfully transmitted by facsimile and confirmed by mail, or if sent by registered mail or recorded delivery post (postage prepaid) addressed to the Participant to be notified at the following address:
WHO/EMP:
World Health Organization
Director, Department of Essential Medicines and Health Products
20 Avenue Appia
1211 Geneva 27
Switzerland
Tel. + 41 22 791 3632
Fax. + 41 22 791 4167FDA:
Associate Commissioner for International Programs
Office of International Programs
United States Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
United States of America
Tel. + 1 301 796 4600
Fax. + 1 301 595 7937This Arrangement constitutes the entire understanding of the Participants hereto with respect to the subject matter hereof and shall not be modified except by mutual agreement in writing.
This Arrangement shall not in any way affect any prior arrangements between FDA and WHO, including any subdivision of WHO, relating to the disclosure of different information (other than the Information) for a different purpose (other than the Purpose).
The Receiving Participant will promptly inform the Disclosing Participant of any circumstances or changes that would affect its ability to honour the commitments in this Arrangement.
Nothing in or relating to this Arrangement shall imply an obligation on the part of WHO to submit to any national legislation or jurisdiction, or be deemed a waiver of any of the privileges and immunities of WHO under any national or international law, convention or agreement.
In the unlikely event that any difference shall arise in the interpretation or application of this Arrangement, the matter shall be submitted to the Director of the Office of Global Health Affairs within the U.S. Department of Health and Human Services and to the Assistant Director-General responsible for General Management of the World Health Organization, who will settle the question personally and jointly or through their duly authorized representatives.
Signed on Behalf of FDA
__________/S/_______________
Name: Dara A. Corrigan
Title: Acting Deputy Commissioner for Global Regulatory Operations and Policy
United States Food and Drug Administration
Date:
Signed on Behalf of WHO/EMP
__________/S/_______________
Name: Dr. Suzanne Hill
Title: Director, Department of Essential Medicines and Health Products
World Health Organization
Date: 8-31-17
Content current as of:
03/29/2018
Below You Can Find All Current Confidentiality Commitment Documents Between WHO and FDA:
WHOFDA-WHO/EMP
INN Program 09/18/2017 WHO FDA-WHO/EMP [Pdf 550 KB] – Update on WHO/EMP
Update On Confidentiality Commitment With WHO’s Access To Medicines And Health Product Division (WHO/EMP)
WHO’s Access to Medicines and Health Product Division (WHO/EMP) confirms that all activities and functions within the scope of WHO’s Department of Essential Medicines and Health Products (WHO/EMP) are now carried out by departments and units within WHO’s Access to Medicines and Health Products Division (MHP). This division is not a new entity or separate organization but a restructured office that remains part of WHO. WHO/MHP confirms that WHO/MHP is bound by the commitments made by WHO/EMP to protect FDA-provided non-public information in the existing arrangement and that WHO/EMP will continue to protect any non-public information previously shared. Content current as of: 04/16/2020
Limited 08/15/2014 WHO FDA-WHO/EHT/DLT
Whereas as part and in the course of the discussions between the United States Food and Drug Administration (FDA) and the World Health Organization, through its Diagnostics and Laboratory Technology Unit of the Department of Essential Health Technologies (WHO/EHT/DLT), aimed at coordinating and facilitating the FDA's regulatory activities and WHO/EHT/DLT activities to assess the acceptability in principle of diagnostics for procurement by United Nations (UN) Agencies (hereinafter also referred to as WHO/EHT/DLT "pre-qualification activities"), each party may (as "the Disclosing Party") disclose to the other party (as "the Receiving Party") certain information relating to its aforesaid activities that it considers non-public, confidential or proprietary to it or parties collaborating with it.
Whereas the aforesaid information may include information protected from public disclosure such as confidential product and/or commercial information; trade secret information; personal privacy information; law enforcement information, and/or internal, pre-decisional information.
Human Medical Devices, Human Drugs, Human Biologics 10/10/11 WHO FDA-WHO/TFI
MUTUAL CONFIDENTIALITY ARRANGEMENT AND COMMITMENT NOT TO PUBLICLY DISCLOSE NON-PUBLIC INFORMATION SHARED BY AND BETWEEN THE U.S. FOOD AND DRUG ADMINISTRATION WITHIN THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES AND THE QUALITY SAFETY AND STANDARDS UNIT OF THE DEPARTMENT OF IMMUNIZATION, VACCINES AND BIOLOGICALS OF THE WORLD HEALTH ORGANIZATION
Whereas as part and in the course of the discussions between the United States Food and Drug Administration within the Department of Health and Human Services (HHS/FDA) and the Quality Safety and Standards Unit of the Department of Immunization, Vaccines And Biologicals of the World Health Organization (WHO/IVB/QSS), aimed at coordinating and facilitating the HHS/FDA's regulatory activities and WHO/IVB/QSS activities to assess the acceptability in principle of vaccines for procurement by United Nations (UN) Agencies (hereinafter also referred to as WHO/IVB/QSS "pre-qualification activities"), each party may (as "the Disclosing Party") disclose to the other party (as "the Receiving Party") certain information relating to its aforesaid activities that it considers non-public, confidential or proprietary to it or parties collaborating with it.
Content current as of: 01/29/2018
Tobacco Products04/12/2011WHOFDA-WHO/IVB/QSS
Whereas, as part and in the course of the discussions between the United States Food and Drug Administration (FDA) and the World Health Organization through its Tobacco Free Initiative (WHO/TFI), aimed at coordinating and facilitating the activities of the FDA and the WHO/TFI with respect to the regulation of tobacco products, each party may (as “the Disclosing Party”) disclose to the other party (as "the Receiving Party") certain information relating to its aforesaid activities that it considers non-public, confidential or proprietary to it or parties collaborating with it.
Human Drugs, Human Biologics07/08/2008WHOFDA/WHO/QSM
MUTUAL CONFIDENTIALITY ARRANGEMENT AND COMMITMENT NOT TO PUBLICLY DISCLOSE NON-PUBLIC INFORMATION SHARED BY AND BETWEEN THE U.S. FOOD AND DRUG ADMINISTRATION WITHIN THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES AND THE QUALITY ASSURANCE AND SAFETY: MEDICINES UNIT OF THE WORLD HEALTH ORGANIZATIONWhereas as part and in the course of the discussions between the United States Food and Drug Administration within the Department of Health and Human Services (HHS/FDA) and the Quality Assurance and Safety: Medicines Unit of the World Health Organization (WHO/QSM), aimed at coordinating and facilitating the HHS/FDA's regulatory activities and WHO/QSM's activities to assess the acceptability in principle of certain health related products for procurement by United Nations (UN) Agencies (hereinafter also referred to as WHO/QSM's "pre-qualification activities"), each party may (as the Disclosing Party") disclose to the other party (as "the Receiving Party") certain information relating to its aforesaid activities that it considers non-public, confidential or proprietary to it or parties collaborating with it.
Prequalification of Medical Products. Update on FDA/WHO/QSM Confidentiality Commitment 08/11/2005 As of Quarter 4 of 2013, the Quality Assurance and Safety Medicines Unit of the World Health Organization (WHO/QSM) has ceased to exist, and all its functions and responsibilities have been absorbed by the Regulation of Medicines and other Health Technologies (RHT) Unit. RHT provided a statement committing to implement the 2005 QSM Confidentiality Commitment as written.
Content current as of: 05/31/2019
Related FDA Links For Your Reviewing Pleasure:
IOJ is blessed to carry the responsibility of being one of upwards of only 10 lawsuits that includes authenticated testimony by Dr. Yeadon, former VP of Pfizer.
You are being called upon to help hold wrongdoers accountable.
You can support Interest of Justice in the mission to file multiple critically important global legal actions against WHO, FDA, CDC, EMA and wrongdoer States (including a solid claim for crimes against humanity) by blessing this mission with a generous donation today.
BE THE PERSISTENCE! DO SOMETHING BOLD! 
If You haven't Signed The Notice And Demands Yet, Please Go Here To Sign And Share Now!
Sign here and demand we Don’t Let Pfizer Get Away With The Greatest Crime In History! Give Global Notice Of: War Room/DailyClout Pfizer Documents Analysis Volunteers’ Reports eBook: Data That Pfizer, FDA Tried to Conceal
Sign here to demand to stop the proposed IHR amendments
Sign Here to demand to stop vaccine passports
Sign here to support stop the ‘Pandemic Treaty’
Sign here to support IOJ’s CRIMINAL Charges for crimes against humanity and breach of ethics against key W.H.O. Staff Director General and Chief Scientist (and her successor Jeremy Farrar).
Sign here and demand IOJ’s OPEN LETTER & Questions Sent To Klaus Schwab. RE: DAVOS “Welcoming Remarks & Special Address”
Notice And Demand.Org (The main website hosting all the demands)
***More Actions Coming Soon!
DO YOU AGREE ITS TIME TO SUE THE W.H.O. FOR INTERNATIONAL WRONGDOING AND BREACH OF ETHICS & RESEARCH STANDARDS DUTIES?
Watch Interest of Justice Set Strict Limits For The W.H.O.:
You probably DO have some idea of how much appreciated that is - and how desperately needed!
Thank you! It is so inspiring and uplifting to see the progress IOJ is making. The TRUTH will prevail!